<DOC>
	<DOCNO>NCT00694161</DOCNO>
	<brief_summary>Open-label , multicenter , international , single-treatment study design determine TTR stabilization well Fx-1006A safety tolerability , effect clinical outcome patient V122I wild-type TTR amyloid cardiomyopathy . The study conduct two part . Part 1 include six-week dosing period enrol patient self-administer oral Fx-1006A 20 mg soft gelatin capsule daily six week . At Week 6 , blood sample collect patient determine TTR stabilization . Patients complete Week 6 visit continue take daily oral Fx 1006A 20 mg total 12 month Part 2 study . If determine patient stabilize Week 6 ( base TTR stabilization data ) , patient discontinue study . Safety clinical outcome evaluate Part 2 study . Two whole blood sample pharmacodynamic assessment ( TTR stabilization ) pharmacokinetic assessment ( Fx-1006A concentration well calculate steady-state parameter ) collect Baseline Week 6 . At Months 6 12 , two whole blood sample collect pharmacodynamic assessment , four whole blood sample ( two sample per time point ) collect pharmacokinetic assessment utilized population pharmacokinetic modeling . Echocardiography , chest x-ray , cardiac MRI , 24-hour Holter monitoring conduct Baseline , Months 6 12 . Six-minute walk test quality life utilize Patient Global Assessment , KCCQ , SF-36 assess Baseline , Months 3 , 6 , 12 . NYHA Classification assess Baseline , Week 6 , Months 3 , 6 , 12 . Serum marker troponin I T , NT-pro-BNP level assess study visit . Safety tolerability assess throughout study . Vital sign , 12-lead ECG , blood urine sample clinical laboratory test ( serum chemistry , hematology , coagulation panel , urinalysis ) , AEs , concomitant medication ( include diuretic usage ) assess study visit . Abbreviated physical examination conduct Baseline , Weeks 2 6 , Months 3 6 , complete physical examination conduct Month 12 . Clinic visit conduct Screening ( Days -30 -1 ) Baseline ( Day 0 ) ; procedure schedule Baseline visit may conduct period one week accommodate patient schedule . All Baseline procedure must complete prior first self-administered dose Day 1 . Day 1 define administration first dose study medication , patient self-administer home . During treatment , clinic visit conduct Week 2 ( ± 2 day ) , Week 6 ( ± 1 week ) , Month 3 ( ± 1 week ) , Month 6 ( ± 2 week ) , Month 12 ( ± 2 week ) . Procedures schedule Month 6 12 visit may occur one week visit window accommodate patient schedule . Monthly telephone contact ( ± 1 week schedule date ) make month clinical site visit schedule ( Months 4 , 5 , 7 , 8 , 9 , 10 , 11 ) assessment AEs concomitant medication . A final telephone contact ass AEs concomitant medication usage make 30 day last dose study medication patient . Patients discontinue study time final visit perform , include safety assessment , time discontinuation . Any patient discontinue Month 6 visit also exploratory assessment perform .</brief_summary>
	<brief_title>The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>1 . Patient &gt; 40 yearsold . 2 . Patient participate FoldRx Study Fx001 ( TRACS ) OR Patient document TTR amyloid cardiomyopathy NYHA Classification I II . TTR amyloid cardiomyopathy define : 1 . Variant TTR amyloid cardiomyopathy define : V122I genotype presence amyloid cardiac biopsy tissue ( determine congo red stain , alcin blue stain , immunohistochemical TTR analysis ) , 2 . Variant TTR amyloid cardiomyopathy define : V122I genotype , evidence cardiac involvement echocardiography leave ventricle wall thickness &gt; 12 mm presence amyloid noncardiac biopsy tissue ( determine congo red stain , alcin blue stain , immunohistochemical TTR analysis ) , 3 . Wildtype TTR amyloid cardiomyopathy define : normal TTR genotype presence TTR amyloid deposit cardiac biopsy tissue ( determine congo red stain immunohistochemical TTR analysis ) , 4 . Wildtype TTR amyloid cardiomyopathy define : normal TTR genotype , evidence cardiac involvement echocardiography leave ventricle wall thickness &gt; 12 mm presence TTR amyloid deposit noncardiac biopsy tissue ( determine congo red stain immunohistochemical TTR analysis ) . 3 . Patient 's symptom congestive heart failure ( CHF ) optimally manage prior baseline , assess Principal Investigator . Optimal CHF management include stable drug regimen ≥ 4 week prior enrollment stable dose beta blocker ≥ 3 month prior enrollment . 4 . If female , patient postmenopausal . If male female partner childbearing potential , willing use acceptable method birth control duration study least 3 month last dose study medication . 5 . Patient , opinion Investigator , willing able comply study medication regimen study requirement 1 . Chronic use nonprotocol approve nonsteroidal antiinflammatory drug ( NSAIDs ) , define great 34 times/month . The follow NSAID allow : acetylsalicylic acid , etodolac , ibuprofen , indomethicin , ketoprofen , nabumetone , naproxen , nimesulide , piroxicam , sulindac . 2 . Patient TTR mutation V122I . 3 . Patient primary secondary amyloidosis . 4 . Patient receive prior liver heart transplantation . 5 . Patient positive result hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( antiHCV ) , and/or human immunodeficiency virus ( HIV ) . 6 . Patient renal failure require dialysis . 7 . Patient moderate severe hepatic impairment ( assess ChildPugh ) . 8 . Patient liver function test abnormality : alanine transaminase ( ALT ) and/or aspartate transaminase ( AST ) &gt; 2 time upper limit normal ( ULN ) , medical judgment Investigator , due reduce liver function active liver disease . 9 . Patient prior nonamyloid cardiac disease , myocardial infarction due obstructive coronary artery disease , active nonamyloid cardiomyopathy ( i.e. , symptomatic leave ventricular dysfunction cause amyloid ) , symptomatic valvular heart disease significantly contribute patient 's underlying cardiac sign symptom . 10 . Patient comorbidity anticipate limit survival le 12 month . 11 . Patient receive investigational drug/device another clinical investigational study within 60 day Baseline ( Day 0 ) . 12 . Patient active alcohol substance abuse within 60 day Baseline ( Day 0 ) . 13 . Patient history document noncompliance .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Transthyretin</keyword>
	<keyword>TTR</keyword>
	<keyword>ATTR</keyword>
	<keyword>TTR amyloidosis</keyword>
	<keyword>cardiomyopathy</keyword>
	<keyword>V122I</keyword>
	<keyword>wild-type TTR</keyword>
	<keyword>SSA</keyword>
	<keyword>Patients V122I wild-type TTR amyloid cardiomyopathy</keyword>
</DOC>